The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.

Postremission Therapy for Acute Myeloid Leukemia ¹

Added text ² stating there is evidence suggesting an advantage for allogeneic HSCT in patients with intermediate risk characteristics (cited Jourdan et al. as reference 17, Horan et al. as reference 18, and Michel et al. as reference 19).

Acute Promyelocytic Leukemia ³

Added Montesinos et al. as reference 16 ⁴.

Added text ⁵ to state that the combination of arsenic trioxide and ATRA resulted in a more rapid achievement of complete response and a longer disease-free survival compared to ATRA alone or arsenic alone during induction therapy.

Recurrent Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies ⁶

Added Brethon et al. as reference 7 ⁷.